|
New study: Pine bark reduces perimenopausal symptoms
August 29, 2007A study to be published in an upcoming edition of the Scandinavian Journal of Obstetrics and Gynaecology reveals that Pycnogenol® (pic-noj-en-all), pine bark extract from the French maritime pine tree, reduces "climacteric symptoms" such as hot flashes, depression, panic attacks, cholesterol and other common symptoms associated with women entering menopause transition. The results suggest Pycnogenol® may serve as an alternative treatment to estrogen replacement therapy, which is the most common remedy of pre-menopause ("perimenopausal") symptoms.
According to the U.S. Department of Health and Human Services, perimenopause is the natural part of aging that signals the ending of a woman's reproductive years. It marks the time when a woman's body begins its move into menopause and can last anywhere from two to eight years.
"Pycnogenol® was chosen for this study due to previous research revealing health benefits associated with cognitive function, skin elasticity, nitric oxide stimulation, free radical scavenging and the broadening of antioxidant activity," said Dr. Peter Rohdewald, Institute of Pharmaceutical Chemistry at Germany's University of Munster and a lead researcher of this study. "Achieving these health benefits is key to treating perimenopausal symptoms naturally."
The randomized, double-blind, placebo controlled study was conducted at Ham-Ming Hospital in Taiwan with 155 perimenopausal women. Each day, patients either received 200 mg Pycnogenol® or placebo, and recorded their symptoms using the Women's Health Questionnaire (WHQ). The WHQ consisted of the following: somatic symptoms, depressed mood, vasomotoric symptoms, memory/concentration, attractiveness, anxiety, sexual behavior, sleep problems and menstrual symptoms.
Additionally, patients visited the clinic at one, three and six months following start of treatment. At each visit, BMI, blood pressure, lipid profile and total antioxidant status were recorded.
After six months, LDL (bad) cholesterol dropped by 10 percent with Pycnogenol® treatment compared to placebo. Patients who supplemented with Pycnogenol® also had increased antioxidant levels compared to the placebo group. During treatment, rapid improvement of symptoms was reported from the Pycnogenol® group after one month. All symptoms of the WHQ improved significantly compared to the start of treatment, and patients did not report unwanted side effects. In the placebo group, no significant changes of symptoms were recorded.
"There is a shift away from the use of hormone replacement therapy due to side effects and in its absence women are searching for safe and natural options to help manage their symptoms. This study investigating Pycnogenol® as a potential natural alternative is very encouraging in view of the safety of Pycnogenol® as it does not bear any hormone-like activities at all," said Dr. Rohdewald.
Numerous other published studies reveal Pycnogenol's® effectiveness for women's health, such as relieving menstrual pain and endometriosis, and it is patent-protected for this application. Additional studies reveal Pycnogenol® is a natural anti-inflammatory, which provides the basis for the rationale to use Pycnogenol® to naturally moderate inflammatory pain sensation involved in menstruation.
MWW Group
The randomized, double-blind, placebo controlled study was conducted at Ham-Ming Hospital in Taiwan with 155 perimenopausal women. Each day, patients either received 200 mg Pycnogenol® or placebo, and recorded their symptoms using the Women's Health Questionnaire (WHQ). The WHQ consisted of the following: somatic symptoms, depressed mood, vasomotoric symptoms, memory/concentration, attractiveness, anxiety, sexual behavior, sleep problems and menstrual symptoms.
Additionally, patients visited the clinic at one, three and six months following start of treatment. At each visit, BMI, blood pressure, lipid profile and total antioxidant status were recorded.
After six months, LDL (bad) cholesterol dropped by 10 percent with Pycnogenol® treatment compared to placebo. Patients who supplemented with Pycnogenol® also had increased antioxidant levels compared to the placebo group. During treatment, rapid improvement of symptoms was reported from the Pycnogenol® group after one month. All symptoms of the WHQ improved significantly compared to the start of treatment, and patients did not report unwanted side effects. In the placebo group, no significant changes of symptoms were recorded.
"There is a shift away from the use of hormone replacement therapy due to side effects and in its absence women are searching for safe and natural options to help manage their symptoms. This study investigating Pycnogenol® as a potential natural alternative is very encouraging in view of the safety of Pycnogenol® as it does not bear any hormone-like activities at all," said Dr. Rohdewald.
Numerous other published studies reveal Pycnogenol's® effectiveness for women's health, such as relieving menstrual pain and endometriosis, and it is patent-protected for this application. Additional studies reveal Pycnogenol® is a natural anti-inflammatory, which provides the basis for the rationale to use Pycnogenol® to naturally moderate inflammatory pain sensation involved in menstruation.
MWW Group
Perimenopausal News and Current Perimenopausal Events RSSEstrogen therapy helps or hurts the brain depending on reproductive status
Estrogen therapy may limit stroke damage if started close to, but not long after reproductive cycles are over, according to a new animal study. The results were presented Sunday, June 15, at The Endocrine Society's 90th Annual Meeting in San Francisco.
Experts call for better research into link between women's hormones and mood disorders
Countless movies and TV shows make light of women's so-called "moodiness", often jokingly attributing it to their menstrual cycle or, conversely, to menopause.
Altered sex hormone levels, higher body temp affects sleep quality in postmenopausal women
In an examination of potential relationships between objective sleep measures, nocturnal sex hormone levels, and the nocturnal course of body temperature of older postmenopausal women.
Researchers identify 5 genetic variations associated with risk of venous thrombosis in women
Researchers have identified new genetic variations that may be associated with the risk of developing nonfatal venous thrombosis in postmenopausal women.
Hormone replacement therapy may improve trip down memory lane
Many women experience declines in their memory during and after menopause, a change thought to be due, in part, to the rapid hormonal changes they weather during that time.
Stanford researcher links hot flashes to insomnia
Millions of women experience menopause each year, and many find themselves having to cope with a plethora of unpleasant symptoms. Hot flashes, headaches and mood swings all come with the territory and, for some women, so does insomnia.
Severe hot flashes associated with chronic insomnia
Women who have severe hot flashes may have more chronic sleep problems than women who do not.
UVa Participates in Landmark Breast Cancer Screening Trial
Digital mammography that uses computers to detect breast cancer found significantly (up to 28%) more cancers than screen film mammography in women 50 and younger, premenopausal and perimenopausal women, and women with dense breasts, according to results from one of the largest breast cancer screening studies ever performed.
Digital Mammography Trial Results Announced
Preliminary results from a large, clinical trial of digital vs. film mammography show no difference in detecting breast cancer for the general population of women in the trial.
More older women are retaining 'young' breasts causing potential screening problems
Many of today's generation of postmenopausal women have breast tissue more akin to that of younger women. This makes it harder for mammograms to pick up tumours or early signs of breast cancer in some over 50s and may also lead to unnecessary biopsies because of uncertainty in reading the results, a meeting of screening specialists will hear today (Tuesday 16 March). Mammogram samples from a screening programme in the Netherlands showed that a quarter of women aged 50 to 69 had the 'dense'[1] mammographic breast patterns more normally associated with younger women. Among 50 to 54-year-olds the proportion was 44%. Radiologist Dr Fred van der Horst said no one really knew why the change had o
More Perimenopausal News Articles
| © 2008 BrightSurf.com |